Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

Anaptysbio Q1 2026 Results: Net Income $3.88M, Down 74.4% YoY

AnaptysBio reported net income of $3.9 million for the quarter ended September 30, 2026, compared to $15.1 million in the prior year period. The company's financial structure has shifted significantly following the spin-off of its Biopharma segment, which is now presented as discontinued operations.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Revenue30.376.3
Profit before tax3.356.6
Net income3.915.1
EPS (diluted, $ a share)$0.11$0.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-74.4%
Revenue, year on year-60.3%
Operating margin65.7%
Source

10-Q filed with the SEC, NASDAQ: ANAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Anaptysbio, Inc: key numbers

Share price
$45.73Close, Nov 16
Market cap
$1.37B
Shares outstanding
29.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Anaptysbio, Inc

All →
4:17 PM ET 8-K
Financial Results

Anaptysbio Financial Results

AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026, highlighted by $1.0 billion in global net sales of Jemperli for the first nine months of 2026. The company is currently awaiting a court judgment in its litigation against GSK and Tesaro, where it is seeking the reversion of Jemperli rights as a remedy.

Counterparty
GSK

“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications.”

Daniel Faga, president and chief executive officer

“We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”

Daniel Faga, president and chief executive officer
5:48 PM ET Form 4
Insider Selling

Anaptysbio Director Hollings Renton Sells $249K of Stock

Hollings Renton, Director, sold 5,000 shares of Anaptysbio, Inc at $49.87 a share, worth $249K in total on Oct 1, 2026. Shares held after the trade: 10,995 (-31.3%).

Value
$249K
Shares
5,000
Price
$49.87
Role
Director
Holding change
-31.3%
Trade date
Oct 1, 2026
4:21 PM ET 8-K
Financial Results

Anaptysbio Financial Results

AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, highlighted by $644 million in global net sales for Jemperli, representing 34% year-over-year growth. The company is awaiting a court judgment in its litigation with GSK and Tesaro expected by Q1 2027 and anticipates FDA approval for Quimilza in December 2026.

Counterparty
GSK
Term
Q2 2026

“Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro.”

Daniel Faga, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.